149 related articles for article (PubMed ID: 17255829)
1. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
Hyams JS; Wilson DC; Thomas A; Heuschkel R; Mitton S; Mitchell B; Daniels R; Libonati MA; Zanker S; Kugathasan S;
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab for active Crohn's disease.
Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy.
Dudley-Brown S; Nag A; Cullinan C; Ayers M; Hass S; Panjabi S
Gastroenterol Nurs; 2009; 32(5):327-39. PubMed ID: 19820441
[TBL] [Abstract][Full Text] [Related]
6. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
7. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.
Baldassano R; Braegger CP; Escher JC; DeWoody K; Hendricks DF; Keenan GF; Winter HS
Am J Gastroenterol; 2003 Apr; 98(4):833-8. PubMed ID: 12738464
[TBL] [Abstract][Full Text] [Related]
8. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
Hommes DW; Mikhajlova TL; Stoinov S; Stimac D; Vucelic B; Lonovics J; Zákuciová M; D'Haens G; Van Assche G; Ba S; Lee S; Pearce T
Gut; 2006 Aug; 55(8):1131-7. PubMed ID: 16507585
[TBL] [Abstract][Full Text] [Related]
9. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB
Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633
[TBL] [Abstract][Full Text] [Related]
11. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.
Thayu M; Leonard MB; Hyams JS; Crandall WV; Kugathasan S; Otley AR; Olson A; Johanns J; Marano CW; Heuschkel RB; Veereman-Wauters G; Griffiths AM; Baldassano RN;
Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1378-84. PubMed ID: 19081527
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Rudick RA; Sandrock A
Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.
Feagan BG; Sandborn WJ; Hass S; Niecko T; White J
Am J Gastroenterol; 2007 Dec; 102(12):2737-46. PubMed ID: 18042106
[TBL] [Abstract][Full Text] [Related]
15. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH.
Crandall W; Hyams J; Kugathasan S; Griffiths A; Zrubek J; Olson A; Liu G; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano RN
J Pediatr Gastroenterol Nutr; 2009 Aug; 49(2):183-90. PubMed ID: 19561542
[TBL] [Abstract][Full Text] [Related]
16. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
[TBL] [Abstract][Full Text] [Related]
17. Natalizumab use in pediatric multiple sclerosis.
Huppke P; Stark W; Zürcher C; Huppke B; Brück W; Gärtner J
Arch Neurol; 2008 Dec; 65(12):1655-8. PubMed ID: 19064754
[TBL] [Abstract][Full Text] [Related]
18. Effects of natalizumab, an alpha4 integrin inhibitor, on fertility in male and female guinea pigs.
Wehner NG; Skov M; Shopp G; Rocca MS; Clarke J
Birth Defects Res B Dev Reprod Toxicol; 2009 Apr; 86(2):108-16. PubMed ID: 19283862
[TBL] [Abstract][Full Text] [Related]
19. Immunotoxicity profile of natalizumab.
Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of natalizumab for formulary consideration.
Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT
Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
